[Mycological aspects and susceptibility in vitro the yeast of the genus Candida from HIV-positive patients in the State of Mato Grosso].

INTRODUCTION Candidiasis is one of the most common fungal infections among patients infected by human immunodeficiency virus. The present study aimed to characterize yeasts of the genus Candida from distinct clinical samples from HIV-positive patients and determine the in vitro susceptibility profile to five antifungal drugs. METHODS Characterization of Candida sp was achieved using the classic methodology: biochemical (zymogram and auxanogram) and micromorphology (germinative tube growth test and slide microculture) tests. Genotypic technique (PCR) and identification by the commercial method API 20C AUX (Biomeriéux) were also performed. To determine the in vitro susceptibility profile, five antifungal drugs were used (ketoconazole, fluconazole, itraconazole, voriconazole and amphotericin-B) following a commercially available method, the Etest. RESULTS The procedure isolated 105 yeasts of the genus Candida from 102 HIV-infected patients. Of these, 82 (78.1%) were characterized as Candida albicans, 8 (7.6%) as C. parapsilosi s, 8 (7.6%) C. tropicalis, 4 (3.8%) C. krusei, 2 (1.9%) C. glabrata, and 1 (1%) as C. guiilliermondii. CONCLUSIONS Considering the general profile of sensitivity, 60% of isolates were susceptible to all the antifungal drugs tested; however, the species C. tropicalis and C. krusei showed a tendency toward higher MICs to azoles than those obtained for C. albicans, suggesting resistance.

[1]  C. Bedout,et al.  Sensibilidad a fluconazol y voriconazol de aislamientos de Candida spp., obtenidos de mucosa oral de pacientes con sida , 2007 .

[2]  Eliana Guilhermetti,et al.  Identificação microbiológica e sensibilidade in vitro de Candida isoladas da cavidade oral de indivíduos HIV positivos , 2007 .

[3]  Raquel Ballesté,et al.  Evaluación del desempeño diagnóstico del medio de difusión en agar Etest® para el estudio de sensibilidad a los antifúngicos , 2006 .

[4]  M. Hirata,et al.  Molecular identification of Candida dubliniensis isolated from oral lesions of HIV-positive and HIV-negative patients in São Paulo, Brazil. , 2006, Revista do Instituto de Medicina Tropical de Sao Paulo.

[5]  M. Pfaller.  Antifungal susceptibility testing methods. , 2005, Current drug targets.

[6]  J. Lopez-Ribot,et al.  Point prevalence, microbiology and antifungal susceptibility patterns of oral Candida isolates colonizing or infecting Mexican HIV/AIDS patients and healthy persons. , 2005, Revista iberoamericana de micologia.

[7]  D. Swinne,et al.  Actividad in vitro del voriconazol, fluconazol, itraconazol y anfotericina B contra levaduras no Candida albicans , 2005 .

[8]  D. Swinne,et al.  In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates. , 2005, Revista iberoamericana de micologia.

[9]  K. Nishimura,et al.  Oral Candida flora from Brazilian human immunodeficiency virus-infected patients in the highly active antiretroviral therapy era. , 2004, Memorias do Instituto Oswaldo Cruz.

[10]  G. JorgePérez,et al.  Susceptibilidad antifúngica de Candida albicans recuperadas de pacientes con SIDA y candidiasis orofaríngea y esofágica: Experiencia con Etest® , 2003 .

[11]  F. Barchiesi,et al.  Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy. , 2002, The Journal of antimicrobial chemotherapy.

[12]  M. Vaneechoutte,et al.  Susceptibility Testing of Fluconazole by the NCCLS Broth Macrodilution Method, E-Test, and Disk Diffusion for Application in the Routine Laboratory , 2002, Journal of Clinical Microbiology.

[13]  N. Johnson,et al.  Oral manifestations of an HIV positive cohort in the era of highly active anti-retroviral therapy (HAART) in South London. , 2002, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[14]  F. Queiroz-Telles,et al.  Multicenter Brazilian study of oral Candida species isolated from AIDS patients. , 2002, Memorias do Instituto Oswaldo Cruz.

[15]  J. Castilla,et al.  Oral candidiasis as a clinical marker related to viral load, CD4 lymphocyte count and CD4 lymphocyte percentage in HIV-infected patients. , 2002, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[16]  P. Connolly,et al.  Does Long-Term Itraconazole Prophylaxis Result in In Vitro Azole Resistance in Mucosal Candida albicans Isolates from Persons with Advanced Human Immunodeficiency Virus Infection? , 2000, Antimicrobial Agents and Chemotherapy.

[17]  G. Quindós,et al.  [In vitro antifungal resistance in Candida albicans from HIV-infected patients with and without oral candidosis.]. , 1999, Revista iberoamericana de micologia.

[18]  G. Quindós,et al.  Resistencia in vitro a los antifúngicos en Candida albicans de pacientes infectados por el VIH con y sin candidosis oral , 1999 .

[19]  C. R. Paula,et al.  Drug resistance of yeasts isolated from oropharyngeal candidiasis in aids patients , 1998 .

[20]  C. Kurtzman,et al.  Rapid Identification of Candida albicansand Other Human Pathogenic Yeasts by Using Short Oligonucleotides in a PCR , 1998, Journal of Clinical Microbiology.

[21]  E. Andrews,et al.  Genus Helicobacter: an expanding taxonomic group, with zoonotic characteristics , 1998 .

[22]  W. Strull,et al.  Fluconazole-resistant Candida in AIDS patients. Report of two cases. , 1993, Oral surgery, oral medicine, and oral pathology.